Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review

Lily Andrews, Zak Thornton, Saanwalshah S Saincher, Ian Y Yao, Sarah Dawson, Luke McGuinness, Hayley E Jones, Sarah Jefferies, Susan C Short, Hung-Yuan Cheng, Alexandra S J McAleenan, Julian P T Higgins, Kathreena M Kurian*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

31 Citations (Scopus)
124 Downloads (Pure)

Abstract

Abstract
Background
Detailed prevalence estimates of BRAFV600 mutations and BRAF inhibitor (BRAFi) treatment responses in V600-mutant glioma will inform trial development.

Methods
Our systematic review analysed overall prevalence of BRAFV600 mutations in glioma and BRAFi treatment response.

Results
Based on 13,682 patients in 182 publications, the prevalence of BRAFV600 in epithelioid glioblastoma (eGBM) was 69% [95% CI: 45-89%]; pleomorphic xanthoastrocytoma (PXA): 56% [48-64%] anaplastic pleomorphic xanthoastrocytoma (aPXA): 38% [23-54%], ganglioglioma (GG): 40% [33-46%], and anaplastic ganglioglioma (aGG): 46% [18-76%]. Prevalence in astroblastoma was 24% [8-43%], desmoplastic infantile astrocytoma (DIA): 16% [0-57%], subependymal giant cell astrocytoma (SEGA): 8% [0-37%], dysembryoplastic neuroepithelial tumour (DNET): 3% [0-11%], diffuse astrocytoma (DA): 3% [0-9%], and pilocytic astrocytoma (PA): 3% [2-5%].We reviewed 394 V600-mutant gliomas treated with BRAFi from 130 publications. 129 paediatric low-grade gliomas showed 4 (3.1%) complete response (CR); 53 (41.1%) partial response (PR); 64 (49.6%) stable disease (SD) and 8 (6.2%) progressive disease (PD). 25 paediatric high-grade gliomas showed CR; PR; SD; PD in 4 (16.0%); 10 (40.0%), 4 (16.0%); and 7 (28.0%) respectively. 39 adult low-grade gliomas showed CR; PR; SD; PD of 4 (10.3%); 17 (43.6%); 16 (41.0%) and 2 (5.1%) respectively. 97 adult high-grade gliomas showed CR; PR; SD; PD of 6 (6.2%); 31 (32.0%); 27 (27.8%); and 33 (34.0%) respectively.

Conclusions
BRAFV600 prevalence is highest in eGBM, PXA, aPXA, GG, aGG and lower in astroblastoma, DIA, SEGA, DNET, DA and PA. Our data provides the rationale for adjuvant clinical trials of BRAFi in V600-mutant glioma.
Original languageEnglish
Article numbernoab247
JournalNeuro-oncology
Early online date28 Oct 2021
DOIs
Publication statusE-pub ahead of print - 28 Oct 2021

Structured keywords

  • ICEP

Fingerprint

Dive into the research topics of 'Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review'. Together they form a unique fingerprint.

Cite this